Enterprise Value to EBITDA (EV/EBITDA)
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)
Pfizer Inc., EBITDA calculation
US$ in millions
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Item | Description | The company |
|---|---|---|
| EBITDA | To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. | Pfizer Inc. EBITDA increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
Enterprise Value to EBITDA Ratio, Current
Pfizer Inc., current EV/EBITDA calculation, comparison to benchmarks
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | 201,713) |
| Earnings before interest, tax, depreciation and amortization (EBITDA) | 9,557) |
| Valuation Ratio | |
| EV/EBITDA | 21.11 |
| Benchmarks | |
| EV/EBITDA, Competitors1 | |
| AbbVie Inc. | 19.86 |
| Amgen Inc. | 13.79 |
| Bristol-Myers Squibb Co. | 7.52 |
| Danaher Corp. | 23.92 |
| Eli Lilly & Co. | 83.47 |
| Gilead Sciences Inc. | 12.10 |
| Johnson & Johnson | 16.07 |
| Merck & Co. Inc. | 39.41 |
| Moderna Inc. | — |
| Regeneron Pharmaceuticals Inc. | 15.70 |
| Thermo Fisher Scientific Inc. | 20.11 |
| EV/EBITDA, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | 22.00 |
| EV/EBITDA, Industry | |
| Health Care | 18.53 |
Based on: 10-K (reporting date: 2023-12-31).
1 Click competitor name to see calculations.
If the company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.
Otherwise, if the company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.
Enterprise Value to EBITDA Ratio, Historical
Pfizer Inc., historical EV/EBITDA calculation, comparison to benchmarks
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | 215,041) | 251,039) | 266,077) | 216,485) | 231,815) | |
| Earnings before interest, tax, depreciation and amortization (EBITDA)2 | 9,557) | 41,031) | 30,793) | 13,723) | 25,266) | |
| Valuation Ratio | ||||||
| EV/EBITDA3 | 22.50 | 6.12 | 8.64 | 15.78 | 9.17 | |
| Benchmarks | ||||||
| EV/EBITDA, Competitors4 | ||||||
| AbbVie Inc. | 20.79 | 13.31 | 13.44 | 21.34 | 13.68 | |
| Amgen Inc. | 14.13 | 12.97 | 13.22 | 12.24 | 12.26 | |
| Bristol-Myers Squibb Co. | 6.51 | 9.46 | 8.65 | 34.35 | 23.84 | |
| Danaher Corp. | 26.41 | 18.42 | 21.05 | 26.68 | 25.23 | |
| Eli Lilly & Co. | 85.33 | 37.74 | 29.85 | 23.67 | 21.40 | |
| Gilead Sciences Inc. | 10.41 | 13.89 | 8.57 | 24.90 | 11.77 | |
| Johnson & Johnson | 16.45 | 14.78 | 14.47 | 18.20 | 16.28 | |
| Merck & Co. Inc. | 51.30 | 13.91 | 12.18 | 16.05 | 13.66 | |
| Moderna Inc. | — | 4.52 | 3.77 | — | — | |
| Regeneron Pharmaceuticals Inc. | 20.16 | 15.27 | 6.68 | 12.70 | 14.80 | |
| Thermo Fisher Scientific Inc. | 21.83 | 20.25 | 20.21 | 18.72 | 19.74 | |
| EV/EBITDA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 23.42 | 13.10 | 12.43 | 19.64 | 14.94 | |
| EV/EBITDA, Industry | ||||||
| Health Care | 19.08 | 13.35 | 13.31 | 16.61 | 14.16 | |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
3 2023 Calculation
EV/EBITDA = EV ÷ EBITDA
= 215,041 ÷ 9,557 = 22.50
4 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| EV/EBITDA | Enterprise value to earnings before interest, tax, depreciation and amortization is a valuation indicator for the overall company rather than common stock. | Pfizer Inc. EV/EBITDA ratio decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |